Recommendations for rotavirus vaccination: A worldwide perspective

Vaccine

Volumn 28, Issue 31, 2010, Pages 5100-5108

  Rodrigo, Carlos ^a   Salman, Nuran ^b   Tatochenko, Vladimir ^c   Mészner, Zsofia ^d   Giaquinto, Carlo ^e  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Institute of Child Health   (Turkey)

^c Russian Academy of Medical Chemistry   (Russian Federation)

^d National Institute of Child Health   (Hungary)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

Guidelines; Rotavirus; Vaccine

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; GASTROENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SUPERINFECTION; VACCINATION; EVIDENCE BASED MEDICINE; PUBLIC HEALTH; ROTAVIRUS INFECTIONS; VIROLOGY;

EVIDENCE-BASED MEDICINE; GASTROENTERITIS; GUIDELINES AS TOPIC; HUMANS; PUBLIC HEALTH; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION;

EID: 77954761520     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.108     Document Type: Article

References (98)

1. O'Ryan M. Rotarix (RIX4414): an oral human rotavirus vaccine. Expert Rev Vaccines 2007, 6(February (1)):11-19.
2. Vesikari T., Van Damme P., Giaquinto C., Gray J., Mrukowicz J., Dagan R., et al. European society for paediatric infectious diseases/European society for paediatric gastroenterology, hepatology, and nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 2008, 46(May (Suppl. 2)):S38-S48.
3. Linhares A.C., Velazquez F.R., Perez-Schael I., Saez-Llorens X., Abate H., Espinoza F., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 2008, 371(April (9619)):1181-1189.
4. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370(November (9601)):1757-1763.
5. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(January (1)):23-33.
6. Van Damme P., Giaquinto C., Huet F., Gothefors L., Maxwell M., Van der Wielden M., et al. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe 2004-2005: the REVEAL study. J Infect Dis 2007, 195(Suppl. 1):S4-S16.
7. Phua K.B., Lim F.S., Lau Y.L., Nelson E.A., Huang L.M., Quak S.H., et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009, 27(October (43)):5936-5941.
8. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362(January (4)):289-298.
9. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(January (1)):11-22.
10. Haber P., Patel M., Izurieta H.S., Baggs J., Gargiullo P., Weintraub E., et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 2008, 121(June (6)):1206-1212.
11. Advisory Committee on Immunization Practices. ACIP presentation slides: update on safety monitoring of RotaTeq (June 2008); 2008 [cited 2 April 2009]. Available from: http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-jun08/12-2-rota-vac.pdf.
12. Advisory Committee on Immunization Practices. ACIP presentation slides: update on safety monitoring of Rotarix (June 2008); 2008 [cited 2 April 2009]. Available from: http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-jun08/16-6-rota-vac.pdf.
13. Linhares A.C., Bresee J.S. Rotavirus vaccines and vaccination in Latin America. Rev Panam Salud Publica 2000, 8(November (5)):305-331.
14. Centers for Disease Control and Prevention. Delayed onset and diminished magnitude of rotavirus activity-United States, November 2007-May 2008. MMRW 2008;57(25):697-700.
15. Parashar U.D., Gibson C.J., Bresse J.S., Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006, 12(February (2)):304-306.
16. Shaw A.R. The rotavirus vaccine saga. Annu Rev Med 2006, 57:167-180.
17. Soriano-Gabarro M., Mrukowicz J., Vesikari T., Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006, 25(January (1 Suppl.)):S7-S11.
18. Gleizes O., Desselberger U., Tatochenko V., Rodrigo C., Salman N., Mezner Z., et al. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr Infect Dis J 2006, 25(January (1 Suppl.)):S12-S21.
19. Parashar U.D., Alexander J.P., Glass R.I. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(August (RR-12)):1-13.
20. Velazquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996, 335(October (14)):1022-1028.
21. Melliez H., Levybruhl D., Boelle P.Y., Dervaux B., Baron S., Yazdanpanah Y. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008, 26(January (5)):706-715.
22. Newall A.T., Beutels P., Macartney K., Wood J., MacIntyre C.R. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007, 25(December (52)):8851-8860.
23. Rheingans R.D., Constenla D., Antil L., Innis B.L., Breuer T. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007, 21(April (4)):205-216.
24. Widdowson M.A., Meltzer M.I., Zhang X., Bresee J.S., Parashar U.D., Glass R.I. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007, 119(April (4)):684-697.
25. Goossens L.M., Standaert B., Hartwig N., Hovels A.M., Al M.J. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008, 26(February (8)):1118-1127.
26. Santosham M., Nelson E.A., Bresee J.S. Implementing rotavirus vaccination in Asia. Vaccine 2007, 25(November (44)):7711-7716.
27. Kingdom of Bahrain Ministry of Health. Recommended immunization schedule for the Expanded Program on Immunization, Bahrain; 2009 [cited 2 April 2009]. Available from: http://www.moh.gov.bh/EN/Immunizations.aspx.
28. Singhal T., Amdekar Y.K., Agarwal R.K. Consensus recommendations on immunization, 2008. Indian Pediatr 2008, 45(August (8)):635-648.
29. Bundesministerium für Gesundheit. Impfplan 2009 Österreich; 2009 [cited 2 April 2009]. Available from: http://www.bmgfj.gv.at/cms/site/attachments/1/4/0/CH0780/CMS1038913010412/impfplan_2009_final.pdf.
30. Conseil Supérieur de la Santé/Hoge Gezondheidsraad. Vaccination contre le rotavirus; 2007 [cited 2 April 2009]. Available from: https://portal.health.fgov.be/pls/portal/docs/PAGE/INTERNET_PG/HOMEPAGE_MENU/ABOUTUS1_MENU/INSTITUTIONSAPPARENTEES1_MENU/HOGEGEZONDHEIDSRAAD1_MENU/ADVIEZENENAANBEVELINGEN1_MENU/ADVIEZENENAANBEVELINGEN1_DOCS/GUIDE_DE_VACCINATION_2008.PDF.
31. Olives J.P., Tounian P., Lamireau T. Rotavirus vaccination in France: recommendations of the French Speaking Group of Pediatric Gastroenterology, Hepatology and Nutrition. Arch Pediatr 2007, 14(October (Suppl. 3)):S194-S196.
32. La Ministre de la Santé. Recommandations générales; 2006 [cited 2 April 2009]. Available from: http://www.sante.gouv.fr/htm/dossiers/vaccin/recom_gene.pdf.
33. Niethammer D., Bartmann P., Heininger U., Huppertz H., Kinet M., Korenke C., et al. Statement on recommendation regarding rotavirus vaccination of the Commission for Infectious Diseases and Vaccination of the German Academy for Child and Adolescent Medicine (DAKJ). Monatsschr Kinderheilkd 2006, 154:1229-1230.
34. Mitteilung der Standigen Impfkommission (STIKO) am Robert Koch-lnstitut. Possibilities for immunization against rotavirus diseases. Med Monatsschr Pharm 2007;30:221-3.
35. Guarino A., Ansaldi F., Ugazio A., Chiamenti G., Bona G., Correra A., et al. Italian Pediatrician's consensus statement on anti-Rotavirus vaccines. Minerva Pediatr 2008, 60(February (1)):3-16.
36. Conseil Supérieur d'Hygiène Luxembourg. Vaccination du nourrisson contre les gastro-entérites à rotavirus; 2006 [cited 2 April 2009]. Available from: http://www.ms.etat.lu/ConseilSuperieurHygiene/CSH_Recommandations.htm.
37. Bernaola Iturbe E., Gimenez Sanchez F., Baca Cots M., de Juan Martin F., Diez Domingo J., Garces Sanchez M., et al. Immunization schedule of the Spanish Association of Pediatrics: recommendations 2008. An Pediatr (Barc) 2008, 68(January (1)):63-69.
38. National Advisory Committee on Immunization. Statement on the recommended use of pentavalent human-bovine reassortant rotavirus vaccine. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2008;34(January (ACS-1)):1-33.
39. Cortese M, Parashar U, Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2009;6(58):1-25.
40. American Academy of Pediatrics. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. Pediatrics 2007;119(January (1)):171-82.
41. Feijo R.B., Cunha J., Krebs L.S. Vaccination schedule for childhood and adolescence: comparing recommendations. J Pediatr (Rio J) 2006, 82(July (3 Suppl.)):S4-S14.
42. Brazilian Ministry of Health. Calendário básico de vacinação (crianças); 2006 [cited 2 April 2009]. Available from: http://www.cva.ufrj.br/informacao/vacinas/calendario/cv-criancas.html.
43. Munoz M.A., Abarca V.K., Luchsinger F.V., Valenzuela B.M., Jimenez de la J.J. Rotavirus vaccine. Statement of the Consultive Committee of Immunizations on behalf of The Chilean Infectious Diseases Society. March 2006. Rev Chilena Infectol 2006, 23(June (2)):124-127.
44. Australian Government. Immunisation provider guidelines: rotavirus immunisation; 2007 [cited 2 April 2009]. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/A008BA27166C36CACA25735A001521AD/$File/rotavirus-provider.pdf.
45. European Medicines Agency. Rotarix Summary of Product Characteristics. 17 November 2008 [cited 2 April 2009]. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/rotarix/rotarix.htm.
46. US Food and Drug Administration. Rotarix Prescribing Information. April 2008 [cited 2 April 2009]. Available from: http://www.fda.gov/cber/label/rotarixLB.pdf.
47. US Food and Drug Administration. RotaTeq Prescribing Information. September 2008 [cited 2 April 2009]. Available from: http://www.fda.gov/cber/label/rotateqlb.pdf.
48. European Medicines Agency. RotaTeq Summary of Product Characteristics. 7 November 2008 [cited 2 April 2009]. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/rotateq/rotateq.htm.
49. de Oliveira L.H., Danovaro-Holliday M.C., Matus C.R., Andrus J.K. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Rev Vaccines 2008, 7(April (3)):345-353.
50. World Health Organization. Immunization schedules by antigen; 2008 [cited 2 April 2009]. Available from: http://www.who.int/immunization_monitoring/en/globalsummary/scheduleselect.cfm.
51. Braine T. Rotavirus vaccine introduction in Mexico sets precedent. Bull World Health Organ 2005, 83(March (3)):167.
52. Nohynek H. The Finnish decision-making process to recommend a new vaccine: From vaccine research to vaccination policy. J Public Health 2008, 16:275-280.
53. Field S., Lohr K. Clinical practice guidelines 1992, National Institute of Health, Washington DC.
54. Grol R., Eccles M., Maisonneuve H., Woolf S. Developing clinical practice guidelines: the European experience. Dis Manage Health Outcomes 1998, 4(5):255-266.
55. Mrukowicz J. Appendix I: methods for the development of evidence-based recommendations. J Pediatr Gastroenterol Nutr 2008, 46(May (Suppl. 2)):S49-S75.
56. Simpson E., Wittet S., Bonilla J., Gamazina K., Cooley L., Winkler J.L. Use of formative research in developing a knowledge translation approach to rotavirus vaccine introduction in developing countries. BMC Public Health 2007, 7:281.
57. Haupt R.M., Isikci O., Kimble W.L., Sotos G.L., Fu J. Physicians' knowledge and attitudes about rotavirus gastroenteritis and rotavirus vaccine. Pediatr Ann 2006, 35(January (1)):54-61.
58. Parashar U.D., Bresee J.S., Gentsch J.R., Glass R.I. Rotavirus. Emerg Infect Dis 1998, 4(October-December (4)):561-570.
59. Schmitt H.J., Booy R., Aston R., Van Damme P., Schumacher R.F., Campins M., et al. How to optimise the coverage rate of infant and adult immunisations in Europe. BMC Med 2007, 5:11.
60. Siegrist C., Desgrandchamps D., Heininger U., Vaudaux B. How to improve communication on vaccine issues at the national level? INFOVAC-PED: an example from Switzerland. Vaccine 2001, 20(October (Suppl. 1)):S98-S100.
61. Gust D.A., Strine T.W., Maurice E., Smith P., Yusuf H., Wilkinson M., et al. Underimmunization among children: effects of vaccine safety concerns on immunization status. Pediatrics 2004, 114(July (1)):e16-e22.
62. Iwamoto M., Saari T.N., McMahon S.R., Yusuf H.R., Massoudi M.S., Stevenson J.M., et al. A survey of pediatricians on the reintroduction of a rotavirus vaccine. Pediatrics 2003, 112(July (1 Pt 1)):e6-e10.
63. Kempe A., Daley M.F., Parashar U.D., Crane L.A., Beaty B.L., Stokley S., et al. Will pediatricians adopt the new rotavirus vaccine?. Pediatrics 2007, 119(January (1)):1-10.
64. Patel M.M., Janssen A.P., Tardif R.R., Herring M., Parashar U.D. A qualitative assessment of factors influencing acceptance of a new rotavirus vaccine among health care providers and consumers. BMC Pediatr 2007, 7:32.
65. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001, 344(February (8)):564-572.
66. Postma M. Public health economics of vaccines in the Netherlands: methodological issues and applications. J Public Health 2008, 16:267-273.
67. Van Damme P., Van der Wielen M., Ansaldi F., Desgrandchamps D., Domingo J.D., Sanchez F.G., et al. Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infect Dis 2006, 6(December (12)):805-812.
68. Lorgelly P.K., Joshi D., Iturriza Gomara M., Gray J., Mugford M. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008, 136(January (1)):44-55.
69. Jit M., Edmunds W.J. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007, 25(May (20)):3971-3979.
70. Daskalaki I., Spain C.V., Long S.S., Watson B. Implementation of rotavirus immunization in Philadelphia. Pennsylvania: high levels of vaccine ineligibility and off-label use. Pediatrics 2008, 122(July (1)):e33-e38.
71. Simonsen L., Viboud C., Elixhauser A., Taylor R.J., Kapikian A.Z. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 2005, 192(September (Suppl. 1)):S36-S43.
72. Advisory Committee on Immunization Practices. Rotavirus vaccination coverage and adherence to the Advisory Committee on Immunization Practices-recommended vaccination schedule-United States, February 2006-May 2007. MMWR Morb Mortal Wkly Rep 2008;57(April (15)):398-401.
73. Lopalco P.-L. Improving vaccination programmes in the European Union. J Public Health 2008, 16:281-285.
74. Atkins D., Best D., Briss P.A., Eccles M., Falck-Ytter Y., Flottorp S., et al. Grading quality of evidence and strength of recommendations. BMJ 2004, 328(June (7454)):1490-1498.
75. Vesikari T. The role of scientific societies in the decision-making process to recommend new vaccines: the example of rotavirus in Europe. J Public Health 2008, 16(4):287-290.
76. Andrus J.K., Toscano C.M., Lewis M., Oliveira L., Ropero A.M., Davila M., et al. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public Health Rep 2007, 122(November-December (6)):811-816.
77. Pan-American Health Organization. Rotavirus model. 2008 [cited 2 April 2009]. Available from: http://www.paho.org/English/AD/FCH/IM/ProVAc_Models.htm.
78. Glass R.I., Bresee J.S., Turcios R., Fischer T.K., Parashar U.D., Steele A.D. Rotavirus vaccines: targeting the developing world. J Infect Dis 2005, 192(September (Suppl. 1)):S160-S166.
79. Block S.L., Vesikari T., Goveia M.G., Rivers S.B., Adeyi B.A., Dallas M.J., et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007, 119(January (1)):11-18.
80. Vesikari T., Clark H.F., Offit P.A., Dallas M.J., DiStefano D.J., Goveia M.G., et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006, 24(May (22)):4821-4829.
81. Steele AD, Tumbo J, Armah G, Reynders J, Scholz F, Bos P, et al. Immunogenicity and reactogenicity of a new live-attenuated oral rotavirus vaccine (RIX4414) when administered concurrently with poliovirus vaccine in African infants. 24th International Congress of Pediatrics, 2004 15-20 August. Cancun, Mexico; 2004.
82. Steele AD, Tumbo J, Armah G, Reynders J, Scholz F, Bos P, et al. Concomitant administration of a live-attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants. 23rd Annual Meeting of the European Society for Paediatric Infectious Diseases, 2005 18-20 May. Valencia, Spain; 2005.
83. Ciarlet M, Sani-Grosso R, Yuan G, Liu G, Heaton P, Gottesdiener K, et al. Safety and immunogenicity of concomitant use of the pentavalent rotavirus vaccine (RotaTeq) and oral poliovirus vaccine 25th Annual Meeting of the European Society for Paediatric Infectious Diseases, 2007 2-4 May. Porto, Portugal; 2007.
84. Ciarlet M., Sani-Grosso R., Yuan G., Liu G.F., Heaton P.M., Gottesdiener K.M., et al. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J 2008, 27(October (10)):874-880.
85. Steele AD, De Vos B, Tumbo J, Reynders J, Scholtz F, Bos P, et al. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine 2008 [e-pub ahead of print] Sep 8.
86. De Mol P., Zissis G., Butzler J.P., Mutwewingabo A., Andre F.E. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986, 2(July (8498)):108.
87. Hanlon P., Hanlon L., Marsh V., Byass P., Shenton F., Hassan-King M., et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987, 1(June (8546)):1342-1345.
88. Lanata C.F., Black R.E., del Aguila R., Gil A., Verastegui H., Gerna G., et al. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine. J Infect Dis 1989, 159(March (3)):452-459.
89. Patriarca P.A., Wright P.F., John T.J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991, 13(September-October (5)):926-939.
90. Su-Arehawaratana P., Singharaj P., Taylor D.N., Hoge C., Trofa A., Kuvanont K., et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 1992, 165(June (6)):1042-1048.
91. Sack D.A., Qadri F., Svennerholm A. Determinants of responses to oral vaccines in developing countries. Ann Nestle 2008, 66:71-79.
92. World Health Organization. Rotavirus vaccines. Wkly Epidemiol Rec 2007;82(August (32)):285-95.
93. Madhi S, Lerumo T, Louw C, Kirsten M, Neuzil K, Steele D, et al. Efficacy of human rotavirus vaccine RIX4414 (Rotarix() in South African infants during the first year of life-an interim report. 8th International Rotavirus Symposium, 2008 3-4 June. Istanbul, Turkey; 2008.
94. Steele ADea. 48th ICAAC/IDSA 46th annual meeting. Washington DC, USA; 2008.
95. Cunliffe N, Kirsten M, Madhi S, Witte D, Ngwira B, Bos P, et al. Efficacy of human rotavirus vaccine RIX4414 in Africra during the first year of life. Abstract 449. European Society of Paediatric Infectious Diseases (ESPID), 2009. Brussels, Belgium; 2009.
96. Newman R.D., Grupp-Phelan J., Shay D.K., Davis R.L. Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics 1999, 103(January (1)):E3.
97. Goveia M.G., Rodriguez Z.M., Dallas M.J., Itzler R.F., Boslego J.W., Heaton P.M., et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007, 26(December (12)):1099-1104.
98. Omenaca F, Sarlangue J, Wysocki J, Nogueira M, Suryakiran PV, Smolenov IV, et al. Immunogenicity of a rotavirus vaccine (RIX4414) in European pre-term infants with different gestational age, 27th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Brussels, Belgium, 9-13 June 2009. Abstract.